AsiDNA Children, Adolescents and Young Adults
Study Details
Study Description
Brief Summary
HGG comprises diffuse midline gliomas (DMG), including diffuse infiltrating brainstem glioma (DIPG), characterised by histone gene mutations, as well as non-DM HGGs mainly in non-midline supratentorial areas, with distinct molecular abnormalities. First-line treatment comprises surgery when doable (non-DM HGGs), and radiotherapy in all cases. Chemotherapy or other drugs in clinical trials may be added during and/or after radiotherapy depending on the HGG subtype. The recurrence rate is nevertheless high in all paediatric and adolescent HGGs. If the time interval between the end of first-line radiotherapy and relapse is long enough, re-irradiation often provides good palliation of symptoms, delays disease progression, improves quality of life and has minimal and manageable toxicity. Nevertheless, strategies to increase efficacy without increasing toxicity in the treatment of recurrent paediatric HGG are much needed.
AsiDNA™ is a DNA repair inhibitor that increases the vulnerability of tumour cells to irradiation without increasing toxicity in healthy tissues. Its novel mechanism of action, based on perturbation of the DNA damage recognition steps in DNA repair, makes its activity specific to tumour cells. Intravenous administration of AsiDNA is currently being investigated in adults with advanced solid tumours. The MTD was not reached during the escalating dose study on the safety, pharmacokinetics and pharmacodynamics of AsiDNA administered as a 1-hour infusion, however an optimal dose range (400-600 mg) was identified for further development, based on the favourable safety and PK profiles. Preclinical studies on AsiDNA added to radiotherapy have shown increased survival and no increase in short- or long-term toxicity due to the high doses of irradiation.
The study will provide paediatric patients who have recurrent HGG with early access to innovation, even during the early drug development stage in adults.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1/Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Radiotherapy + AsiDNA Patients will receive the IMP which is the AsiDNA (etidaligide). AsiDNA will be administered intravenously as a 1-hour infusion. All patients will receive a loading dose for three consecutive days, with Day 1 being the start day of radiotherapy, followed by once weekly administrations during 11 weeks. The infusion of AsiDNA should be administered between 4 and 6 hours before the planned start of radiotherapy. After the administration of AsiDNA, Patients with DIBG will receive a total dose of 18 Gy, delivered in 10 fractions of 1.8 Gy, i.e. 5 fractions per week for 2 weeks, starting on Day 1. Patients with supratentorial non-DMG or DMG will receive a total dose of 36 Gy, delivered in 20 fractions of 1.8 Gy, i.e. 5 fractions per week for 4 weeks, starting on Day 1. |
Drug: AsiDNA
Administration of AsiDNA followed by radiotherapy
|
| Active Comparator: Radiotherapy Patients with DIBG will receive a total dose of 18 Gy, delivered in 10 fractions of 1.8 Gy, i.e. 5 fractions per week for 2 weeks, starting on Day 1. Patients with supratentorial non-DMG or DMG will receive a total dose of 36 Gy, delivered in 20 fractions of 1.8 Gy, i.e. 5 fractions per week for 4 weeks, starting on Day 1. |
Drug: AsiDNA
Administration of AsiDNA followed by radiotherapy
|
Outcome Measures
Primary Outcome Measures
- DLT(Dose-Limiting Toxicities) [8 weeks after treatment initiation]
Dose-limiting toxicities, i.e. grade ≥ 3 toxicities according to NCI-CTCAE version 5.0, considered as at least possibly related to the treatment during the 8 weeks after treatment initiation.
- Activity [3 months after treatment initiation]
3-month progression-free survival (PFS), i.e. the probability for a patient to be alive and free of disease progression based on clinical or radiological criteria, or death from any cause at 3 months after inclusion in the study. Radiological progression will be assessed using RAPNOHGG criteria. Patients lost to follow-up will be counted as failures at the last assessment date.
Secondary Outcome Measures
- Late Onset toxicity [8 weeks and until 12 months after treatment initiation]
Late-onset toxicity, defined as any toxicity, i.e. any AE considered as at least possibly related to treatment, that occurs more than 8 weeks after treatment initiation;
- MR pattern of disease response and of potential treatment-related toxicity, [3 months after treatment initiation]
MR pattern of disease response and of potential treatment-related toxicity, assessed by central review based on morphological and functional imaging features present on the various MR examinations;
- Best objective Response Rate [3 months after treatment initiation]
Best objective response rate, defined as the percentage of patients with complete or partial responses according to RAPNO criteria as assessed by the investigator
- Overall survival [12 months after treatment initiation]
Overall survival, defined as the time from inclusion in the study to death from any cause. Patients alive or lost to follow-up at the cut-off date will be censored at the last date they were known to be alive;
- Palliation of symptoms 1 [3 months after treatment initiation]
Palliation of symptoms, assessed using the Lansky Play Scale (LPS) or Karnofsky
- Palliation of symptoms 2 [3 months after treatment initiation]
Performance Status (KPS)
- Palliation of symptoms 2 [3 months after treatment initiation]
Need for corticosteroids and/or bevacizumab
- Pharmacokinetic parameters of AsiDNA. [1 week after treatment initiation]
Maximal observed drug concentration (Cmax);
- Pharmacokinetic parameters of AsiDNA. [1 week after treatment initiation]
absorption and elimination half-life (t1/2))
- Pharmacokinetic parameters of AsiDNA. [1 week after treatment initiation]
time to reach maximum observed drug concentration (Tmax);
- Pharmacokinetic parameters of AsiDNA. [1 week after treatment initiation]
area under the curve (AUC0-t (experimental time points)
- Pharmacokinetic parameters of AsiDNA. [1 week after treatment initiation]
AUC0-∞ (extrapolated to infinity)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Written informed consent from patient (depending on age) and/or parents or legal guardian;
-
Male or female;
-
Age < 25 years at diagnosis;
-
Recurrent high-grade glioma (HGG), including diffuse midline glioma (DMG) and non-DMG, based on RAPNO criteria confirmed by central radiological review, with or without histology if biopsy performed prior to inclusion;
-
Available tumour material, at least paraffin embedded and preferably also frozen material;
-
For non-DMG HGG, prior radiation dose prescribed ≤ 60 Gy, completed at least 6 months prior to inclusion, with stable disease;
-
Maximum cumulative radiation dose to optic chiasm and optic nerve < 56 Gy and < 54 Gy to upper cervical spine (at level C1);
-
Life expectancy > 2 months at Screening;
-
Lansky score > 50%, not taking into account neurological deficit;
-
No significant abnormality on laboratory tests at Screening, including:
-
Haemoglobin > 9 g/dL;
-
Neutrophils > 1.0 x 109/L;
-
Platelets > 100 x 109/L;
-
Total bilirubin < 1.5 x ULN;
-
AST and ALT< 2.5 x ULN;
-
Serum creatinine < 1.5 x ULN for age;
-
Normal coagulation tests.
-
No organ toxicity > grade 2 according to NCI CTCAE version 5.0 classification, notably cardiovascular, pulmonary or renal diseases, including congenital QT prolongation syndrome, nephrotic syndrome, glomerulopathy, uncontrolled high blood pressure despite appropriate treatment, interstitial pulmonary disease, pulmonary hypertension;
-
Negative serum pregnancy test for women of child-bearing potential, and highly effective birth control method for male and female patients of reproductive potential;
-
Patients covered by social security or health insurance in compliance with the national legislation relating to biomedical research.
Exclusion Criteria:
-
Diffuse infiltrating brainstem glioma extending below the occipital hole;
-
Spinal cord HGG;
-
Radiotherapy less than 6 months prior to inclusion;
-
Asymptomatic HGG;
-
Prior radiation dose prescribed > 60 Gy;
-
Massive intra-tumour haemorrhage;
-
Pseudoprogression (including after central review);
-
Metastatic relapse;
-
Other anticancer treatment, on-going or within less than 4 weeks prior to inclusion;
-
Prior or concurrent malignant disease, other than HGG, diagnosed or treated within 5 years prior to inclusion;
-
Uncontrolled intercurrent disease or active infection;
-
Concomitant disease or other significant medical, psychiatric, or surgical condition, currently uncontrolled by treatment, which may interfere with completion of the study;
-
Patients unable to comply with the protocol for any reason;
-
Organ toxicity > grade 2 according to NCI CTCAE version 5.0 classification, notably cardiovascular, pulmonary or renal diseases, including congenital QT prolongation syndrome, nephrotic syndrome, glomerulopathy, uncontrolled high blood pressure despite appropriate treatment, interstitial pulmonary disease, pulmonary hypertension
-
Breastfeeding or pregnancy.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Chu Angers | Angers | France | 49033 | |
| 2 | Chru Bordeaux | Bordeaux | France | 33076 | |
| 3 | Centre Oscar Lambret | Lille | France | 59020 | |
| 4 | Centre Leon Berard | Lyon | France | 69373 | |
| 5 | Chu La Timone Hopital Enfants | Marseille | France | 13385 | |
| 6 | Chu Nancy | Nancy | France | 54500 | |
| 7 | Institut Curie | Paris | France | 75005 | |
| 8 | Chu Strasbourg | Strasbourg | France | 67098 | |
| 9 | Chu Toulouse | Toulouse | France | 31059 | |
| 10 | Gustave Roussy | Villejuif | France | 94800 |
Sponsors and Collaborators
- Institut Curie
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- IC 2020-21